证券代码：600332 证券简称：白云山 公告编号：2025-080 广州白云山医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 广州白云山医药集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计 划于 2025 年 11 月 28 日（星期五）下午 16:00-17:00 举行 2025 年第 三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第 会议召开时间：2025 年 11 月 28 日(星期五)下午 16:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资 ...

来源：新浪证券-红岸工作室 11月19日，白云山跌0.94%，成交额1.66亿元。两融数据显示，当日白云山获融资买入额1376.71万元， 融资偿还1548.14万元，融资净买入-171.43万元。截至11月19日，白云山融资融券余额合计8.31亿元。 分红方面，白云山A股上市后累计派现109.06亿元。近三年，累计派现43.59亿元。 机构持仓方面，截止2025年9月30日，白云山十大流通股东中，中国证券金融股份有限公司位居第四大 流通股东，持股4727.80万股，持股数量较上期不变。香港中央结算有限公司位居第五大流通股东，持 股2001.09万股，相比上期减少2043.72万股。华泰柏瑞沪深300ETF（510300）位居第七大流通股东，持 股1214.03万股，相比上期减少49.56万股。易方达沪深300医药ETF（512010）位居第八大流通股东，持 股881.01万股，相比上期减少271.42万股。易方达沪深300ETF（510310）位居第十大流通股东，持股 865.06万股，相比上期减少28.60万股。 融券方面，白云山11月19日融券偿还9400.00股，融券卖出0.00股，按当日收盘价计算， ...

Core Insights - Guangzhou Wanglaoji Health Industry Co., Ltd. has increased its registered capital from 900 million RMB to 1 billion RMB, representing an approximate 11% increase, alongside changes in its executive management [1] Company Information - The company was established in February 2012 and is wholly owned by Baiyunshan Pharmaceutical Group Co., Ltd. [1][3] - The legal representative of the company is Chen Kunnan, and its business scope includes retail of edible agricultural products, leasing of land use rights, and non-residential real estate leasing [1][3] Shareholder Structure - Baiyunshan Pharmaceutical Group Co., Ltd. holds 100% of the shares in Guangzhou Wanglaoji Health Industry Co., Ltd. [3]

天眼查工商信息显示，11月17日，王老吉关联公司广州王老吉大健康产业有限公司发生工商变更，注册 资本由9亿人民币增至10亿人民币，增幅约11%，同时发生高管变更。广州王老吉大健康产业有限公司 成立于2012年2月，法定代表人为陈昆南，经营范围包括食用农产品零售、土地使用权租赁、非居住房 地产租赁等。股东信息显示，该公司由白云山（600332）全资持股。 ...

会上，白云山稀核健康与全球医疗科技巨头GE医疗签署战略合作协议，双方将致力在精准医疗与核医 学领域的发展与创新，为充分发挥白云山稀核健康在放射性药物研发、生产与管理专业优势，以及GE 医疗深厚的技术沉淀，推动医学影像前沿技术的提升及转化，共同引领核医学诊疗一体化的发展。此次 合作既是广药集团"科技化""国际化"战略的具体实践，也是跨界资源整合、推动产业升级的重要探索。 白云山稀核健康此次发布的完全自主知识产权医用放射性核素一体化解决方案，成功攻克固体靶系统与 分离纯化技术壁垒，构建了从辐照到核素制备的全链条技术体系；同步推出的镓-68、锆-89、铼-186与 铜-64四大核心医用核素，涵盖精准诊断、靶向治疗及诊疗一体化方向，标志着广药集团已能完全自 主、稳定地制备上述四种关键医用放射性核素以及在多核素药物研发平台的建设上取得了决定性突破。 中证报中证网讯（王珞）11月18日，2025年广药集团、广药白云山（600332）战略合作研讨会在南京举 办。大会汇聚合作伙伴、行业专家及企业代表等430余位嘉宾，搭建起覆盖医药大健康全产业链的高端 对话与资源对接平台，集中发布了广药集团创新战略、创新成果与合作规划，其中核 ...

Policy Developments - The National Medical Products Administration (NMPA) is focusing on the quality supervision of selected drugs in centralized procurement, emphasizing the importance of quality safety and compliance in production [1] - The NMPA will implement comprehensive production inspections and product sampling for selected drugs, optimizing work mechanisms and exploring risk monitoring [1] - The NMPA acknowledges the development of the medical device industry in Chongqing and stresses the need for a robust quality safety responsibility system [2] Drug and Device Approvals - Baiyunshan's subsidiary Zhongyi Pharmaceutical received a registration certificate for the traditional medicine An Gong Niu Huang Wan from Vietnam's Ministry of Health, aiding market expansion [3] - Huyou Pharmaceutical announced that its subsidiary Seacross Pharmaceuticals Ltd. received marketing approvals for multiple products from regulatory authorities in Pakistan, the UK, and North Macedonia [4] - Zhifei Biological's recombinant herpes zoster vaccine (ZFA01) clinical trial application has been accepted by the NMPA, which may enhance vaccine efficacy [5] Capital Market Activities - Puluo Pharmaceutical plans to repurchase shares worth between RMB 180 million and RMB 360 million, with a maximum price of RMB 23 per share [6][7] - Sinovac Biotech received a delisting notice from NASDAQ due to failure to submit its annual report by the deadline, with potential trading suspension imminent [8] Industry Developments - Researchers published a detailed immune response map following pig kidney transplants in brain-dead patient models, identifying key factors for transplant success [9] - Haizheng Pharmaceutical's subsidiary plans to collaborate with the East China Institute for the biomanufacturing of heparin, with a project budget not exceeding RMB 120 million [10] Public Sentiment Alerts - Guangyuyuan announced the resignation of Vice President Wang Junbo due to work adjustments, effective immediately [11] - Medici's shareholder Chen Guoxing plans to reduce his stake by up to 1.64% through trading methods due to personal financial needs [12]

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. has received a drug registration certificate for Angong Niuhuang Pills from the Vietnamese Ministry of Health, which will allow its subsidiary to expand its market presence in Vietnam [1][3]. Group 1: Drug Information - The drug Angong Niuhuang Pills is a prescription traditional Chinese medicine used for clearing heat and detoxifying, as well as calming and opening the orifices [2]. - The registration number for Angong Niuhuang Pills is VNCT-00006-25, and it is manufactured by Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. [1]. Group 2: Financial Performance - In 2024, the sales revenue of Angong Niuhuang Pills in China reached RMB 498,242 million, while the sales revenue for Zhongyi Pharmaceutical was RMB 15,611.83 million [2]. - The total research and development investment for the Angong Niuhuang Pills project by Zhongyi Pharmaceutical has reached approximately RMB 3,279.81 million (unaudited) [2]. Group 3: Market Impact - The registration of Angong Niuhuang Pills is expected to enhance the market competitiveness of the company’s products and facilitate the expansion of its business in Vietnam [3]. - The impact of this registration on the company's current performance is not expected to be significant [3].

Major Events - CICC (03908), Dongxing Securities (601198.SH), and Xinda Securities (601059.SH) plan to merge through absorption and share exchange [1] - Ruian Real Estate (00272) has reached a joint venture arrangement to develop a renewal project in Pudong New District, Shanghai [1] - Baijin Life Sciences (01466) subsidiary intends to invest in Youhuan Bio to create a leading global circRNA technology R&D platform [1] - Code-B (02487) has its new drug application for CU-40105 (self-developed topical finasteride spray) accepted by the National Medical Products Administration [1] - Pony.ai-W (02026) collaborates with SANY Heavy Truck and Dongfeng Liuzhou Motor to jointly develop a fourth-generation autonomous truck family [1] - Qiming Medical-B (02500) announces mid-term clinical results of its innovative transcatheter valve replacement system Cardiovalve from the TARGET study [1] - Wuling Motors (00305) establishes a subsidiary focused on low-speed intelligent driving systems and solutions [1] - Neusoft Ruixin Group (09616) signs a general contracting construction contract with Guangdong College, Chengdu College, and Dalian College [1] - Baiyunshan (00874) receives a drug registration certificate for An Gong Niu Huang Wan from the Vietnam Ministry of Health [1] - Dongfang Electric (01072) and Anhui Energy plan to jointly establish a joint venture to advance the 1 million kilowatt technological innovation experimental wind farm project [1] Operating Performance - Mifus (02556) reports a 45% year-on-year increase in AI+SaaS business revenue for the third quarter [2] - GDS Holdings (09698) reports third-quarter net revenue of 2.887 billion yuan, a year-on-year increase of 10.2% [2] - SF Holding (06936) reports total revenue of 26.454 billion yuan from express logistics, supply chain, and international business in October, a year-on-year increase of 9.79% [2] - Kingsoft Cloud (03896) achieves adjusted net profit of 28.7 million yuan for the first time in the third quarter [2] - Guofu Quantum (00290) issues a positive profit alert, expecting mid-term net profit attributable to shareholders to be approximately 200 to 210 million HKD, turning from loss to profit year-on-year [2] - Kingsoft Software (03888) reports third-quarter profit attributable to shareholders of approximately 213 million yuan, a year-on-year decrease of 48% [2] - Kuaishou-W (01024) reports operating profit of 5.299 billion yuan in the third quarter, a year-on-year increase of 69.9% [2]

Key Points - 合富中国's stock will resume trading on November 20 after completing an investigation into unusual trading fluctuations, confirming normal business operations and no undisclosed significant matters [1] - 中金公司 plans to merge with 东兴证券 and 信达证券, leading to a suspension of its A-shares starting November 20 due to uncertainties surrounding the merger [1] - 大为股份 is progressing with the transition from exploration to mining rights for its lithium battery project in Hunan, having received necessary approvals [1] - 燕东微's major shareholders plan to reduce their stakes by up to 2.5% through block trades or centralized bidding from December 11, 2025, to March 11, 2026 [2] - 中水渔业's major shareholder reduced its stake to 5% after selling 258.88 million shares [3] - 韵达股份 reported a slight decline in express service revenue for October 2025, totaling 4.495 billion yuan, a year-on-year decrease of 0.88% [4] - 倍杰特 intends to acquire a 55% stake in 大豪矿业 for 224.8 million yuan [4] - 辰奕智能 plans to acquire a 55% stake in 华泽电子 through cash [4] - 赣粤高速's actual controller will change from the provincial transportation department to the provincial state-owned assets supervision and administration commission [5] - 东软集团 received a notification for a 4.2 billion yuan contract for intelligent cockpit controllers from a major domestic automotive manufacturer [5] - 海正药业's subsidiary plans to invest in a pet prescription food project [5] - 龙利得's controlling shareholder plans to increase its stake by at least 56 million yuan [6] - 新兴装备's shareholders plan to reduce their stakes by up to 3.13% [6] - 普洛药业 plans to repurchase shares worth between 180 million and 360 million yuan [6]

Core Viewpoint - Da An Gene, a leading company in genetic testing, is set to be acquired by Guangzhou Pharmaceutical Group, which is seen as a potential rescue for the struggling company [1][6]. Group 1: Acquisition Details - Guangzhou Pharmaceutical Group will acquire 16.63% of Da An Gene's shares through Guangzhou Jinkong Group and Guangzhou Health Industry Investment, along with an additional 10% stake at a price of 6.47 yuan per share, totaling 9.08 billion yuan [3]. - Post-acquisition, Guangzhou Pharmaceutical Group will control approximately 26.63% of Da An Gene, while Guangzhou Jinkong Group will retain a 5% stake [3]. - The transaction will not change the actual controller of Da An Gene, which remains under the control of the Guangzhou Municipal Government [3]. Group 2: Financial Performance - Da An Gene experienced a dramatic decline in revenue and net profit, with revenues dropping from 120.5 billion yuan in 2022 to 8.53 billion yuan in 2024, and net profit plummeting from 54.28 billion yuan to a loss of 9.39 billion yuan in the same period [4]. - In the first three quarters of 2025, Da An Gene reported revenues of 5.04 billion yuan, a year-on-year decrease of 14.8%, and a net loss of 1.51 billion yuan, despite a 69.9% increase in losses [5]. - The company has significantly reduced R&D spending by nearly 30%, while marketing expenses surged by 70% [5]. Group 3: Challenges and Management Changes - Da An Gene has faced internal turmoil, including a three-year boardroom conflict that resulted in the exit of the founding technical team and the takeover by new financial stakeholders [5][9]. - The company has also been involved in a corruption scandal related to hospital testing departments and has laid off over 60% of its workforce [5]. - The recent acquisition by Guangzhou Pharmaceutical Group may lead to further personnel changes, raising concerns about the expertise of new management in the IVD sector [6][8]. Group 4: Strategic Outlook - Guangzhou Pharmaceutical Group aims to create a full-chain integration of "testing-diagnosis-drugs" through the acquisition, as its medical device segment has contributed only 1% to its revenue [7]. - There are doubts about the integration of Da An Gene's IVD-focused business with Guangzhou Pharmaceutical Group's existing low-margin medical device operations, which may complicate future collaboration [8]. - The historical context of Guangzhou Pharmaceutical Group's previous unsuccessful ventures into the IVD market raises skepticism about the potential success of this acquisition [9].